About This Event

Guardant Health (Nasdaq: GH), a leading precision oncology company, visits the Nasdaq MarketSite in Times Square. Recently, Guardant Health’s product, Shield, became the first blood test approved by the FDA as a primary screening option for colorectal cancer. The test detects colorectal cancer signals in the bloodstream from DNA that is shed by tumors.

In honor of the occasion, Co-CEOs and Co-Founders, Helmy Eltoukhy and AmirAli Talasaz, ring the Opening Bell.